In December 2024, the Austrian Institute for HTA published a project report on the threshold values in health economic evaluations and decision-making. It concluded that, despite their complexity, implementing thresholds could enhance transparency and efficiency in health systems.
Since January 1, 2025, the Danish Healthcare Quality Institute has been established, replacing the Health Technology Council and the Regions' Clinical Quality Development Program. The Institute comprises three overall focus areas that contribute to patients receiving high and uniform quality treatment across the country and the best possible health for the money.
On December 3, 2024, the Member State Coordination Group on HTA released the 2025 Annual Work Programme for the new joint EU-level HTA framework (Regulation on Health Technology Assessment, HTAR). The framework will be fully operational from January 12, 2025.
In December 2024, the Skåne University Hospital (HTA South) is working on health technology assessments in several areas, including men’s health and neurology.
In February 2024, the Skåne University Hospital is working on several HTAs, including evaluations in the cardiovascular, e-health, endocrine, men’s health, neurology and neurosurgery, orthopedics fields.
On February 5, 2024, NICE published proposed methods and processes to include technology appraisal recommendations in the clinical guidelines and launched a consultation. The deadline for submitting comments is March 15, 2024.
In December 2023, the National Institute for Health and Care Research (NIHR) in England released two MedTech-related assessments in its Health Technology Assessment (HTA) Journal, which concerned ablative and non-surgical therapies for hepatocellular carcinoma and hidradenitis suppurativa treatment. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.
In December 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (middle meningeal artery embolization for chronic subdural hematomas), one Technology Appraisal Guidance (Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes, and one new clinical guideline.
Continuous glucose monitoring (rtCGM) and flash glucose monitoring (FGM) for adults with type 1 diabetes have been evaluated within the "New Methods" framework since June 2023. In November 2023, a simplified method assessment report was published. On December 11, 2023, the Decision Forum for "New Methods" recommended introducing rtCGM and FGM.
In November 2023, the National Institute for Health and Care Research (NIHR) in England released one MedTech-related assessment in its Health Technology Assessment (HTA) Journal, which concerned posterior hypofractionated whole breast radiotherapy for early breast cancer treatment. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.
In November 2023, the National Institute for Health and Care Excellence (NICE) published four new Interventional Procedure Guidance (percutaneous thrombectomy for pulmonary embolism, percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis, biodegradable subacromial spacer insertion for rotator cuff tears, extracorporeal carbon dioxide removal for acute respiratory failure) and one Health Technology Evaluation using early value assessment (virtual reality technologies for treating agoraphobia or agoraphobic avoidance). Also, five clinical guidelines were updated.
On November 13, 2023, the Agency for Health Quality and Assessment of Catalonia released a user guide on the health technology assessment framework: adaptation for digital health technology (DHT) assessment. The guidelines described can be equally useful for HTA agencies, researchers, and developers of DHT, decision-makers, and regulators.